RAF1 and glioma: Among them, Sorafenib, which targets RAF1, can cross the BBB and has been shown to prevent advanced RCC metastasis to the brain.[33] As specific enrichment results for BrMs or gliomas, these kinases hold strong potential as therapeutic strategies for precision medicine.